Boston Scientific Corp. (NYSE: BSX) shares climbed more than 4% in intra-day trading on Wednesday after the medical device maker reported third-quarter earnings and revenue that topped analyst expectations, fueled by robust performance across all business segments.
The company posted adjusted earnings per share (EPS) of $0.75, exceeding the consensus estimate of $0.71. Revenue rose 20.3% year-over-year to $5.07 billion, ahead of forecasts of $4.97 billion. Organic revenue increased 15.3%, beating the company’s prior guidance range of 12% to 14%.
The Cardiovascular segment led the growth with revenue up 22.4%, while the MedSurg segment climbed 16.4%. U.S. sales grew 27% from the year-ago quarter, reflecting strong domestic demand.
Boston Scientific raised its full-year 2025 outlook, now expecting adjusted EPS between $3.02 and $3.04, compared with the consensus of $2.98. For the fourth quarter, management guided for EPS between $0.77 and $0.79, above the $0.76 Wall Street forecast.
